The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 6, 2011, Pages 589-595

  Green, Tamar ^a,b   Weinberger, Ronnie ^c   Diamond, Adele ^d,e   Berant, Michael ^f   Hirschfeld, Leora ^c   Frisch, Amos ^a   Zarchi, Omer ^c,g   Weizman, Abraham ^a,h   Gothelf, Doron ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e BC CHILDREN S HOSPITAL   (Canada)

^f SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^g Interdisciplinary PhD Program in Neuroscience   (Israel)

^h GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; CHILD; CLINICAL ARTICLE; COGNITION; COMORBIDITY; CONNERS RATING SCALE; CONTROLLED STUDY; DAY DREAMING; DREAMING; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMOTION; FEMALE; FOLLOW UP; GENOTYPE; HEADACHE; HETEROZYGOTE; HUMAN; HYPOMANIA; IRRITABILITY; LONG TERM CARE; MALE; MANIA; MEDICAL ASSESSMENT; NEUROLOGIC EXAMINATION; PR INTERVAL; PREFRONTAL CORTEX; PRESCHOOL CHILD; PSYCHOSIS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SADNESS; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TALKING LITTLE; TASK PERFORMANCE; TREATMENT OUTCOME; UNINTERESTED; VELOCARDIOFACIAL SYNDROME; VISION;

ADOLESCENT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CATECHOL O-METHYLTRANSFERASE; CHILD, PRESCHOOL; COGNITION; DIGEORGE SYNDROME; FEMALE; HEART RATE; HETEROZYGOTE; HUMANS; HYPERKINESIS; MALE; METHYLPHENIDATE; PSYCHOMOTOR PERFORMANCE; YOUNG ADULT;

EID: 84555179091     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0042     Document Type: Article

References (42)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
2. Aneja A, Fremont WP, Antshel KM, Faraone SV, AbdulSabur N, Higgins AM, Shprintzen R, Kates WR: Manic symptoms and behavioral dysregulation in youth with velocardiofacial syndrome (22q11.2 deletion syndrome). J Child Adolesc Psychopharmacol 17:105-114, 2007. (Pubitemid 46452086)
3. Antshel KM, Fremont W, Kates WR: The neurocognitive phenotype in velo-cardio-facial syndrome: A developmental perspective. Dev Disabil Res Rev 14:43-51, 2008. (Pubitemid 351716522)
4. Balcioglu A, Ren JQ, McCarthy D, Spencer TJ, Biederman J, Bhide PG: Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice. Neuropharmacology 57:687-693, 2009.
5. Ballard JE, Boileau RA, Sleator EK, Massey BH, Sprague RL: Cardiovascular responses of hyperactive children to methylphenidate. JAMA 236:2870-2874, 1976. (Pubitemid 8011723)
6. Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R: The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry 160:1580-1586, 2003. (Pubitemid 41079542)
7. Bawden HN, MacDonald GW, Shea S: Treatment of children with Williams syndrome with methylphenidate. J Child Neurol 12:248-252, 1997. (Pubitemid 27268570)
8. Berkley RA, Fischer M, Newby RF, Breen MJ: Development of a multi method clinical protocol for assessing stimulant drug response in children with attention deficit disorder. J Clin Child Psychol 17:14-24, 1988.
9. Caplan R, Arbelle S, Guthrie D, Komo S, Shields WD, Hansen R, Chayasirisobhon S: Formal thought disorder and psychopathology in pediatric primary generalized and complex partial epilepsy. J Am Acad Child Adolesc Psychiatry 36:1286-1294, 1997. (Pubitemid 27381286)
10. Charach A, Ickowicz A, Schachar R: Stimulant treatment over five years: Adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 43:559-567, 2004, 2004. (Pubitemid 38812367)
11. Collins P, Roberts AC, Dias R, Everitt BJ, Robbins TW: Perseveration and strategy in a novel spatial self-ordered sequencing task for non-human primates: Effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex. J Cogn Neurosci 10:332-354, 1998. (Pubitemid 28247946)
12. Davidson MC, Amso D, Anderson LC, Diamond A: Development of cognitive control and executive functions from 4 to 13 years: Evidence from manipulations of memory, inhibition, and task switching. Neuropsychologia 44:2037-2078, 2006. (Pubitemid 43993998)
13. Debbane M, Glaser B, David MK, Feinstein C, Eliez S: Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological and behavioral implications. Schizophr Res 84:187-193, 2006. (Pubitemid 44255603)
14. Diamond A, Barnett WS, Thomas J, Munro S: Preschool program improves cognitive control. Science 318:1387-1388, 2007. (Pubitemid 350208940)
15. Diamond A, Briand L, Fossella J, Gehlbach L: Genetic and neuro-chemical modulation of prefrontal cognitive functions in children. Am J Psychiatry 161:125-132, 2004. (Pubitemid 38419317)
16. Diamond A, Prevor MB, Callender G, Druin DP: Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 62:1-208, 1997.
17. Funke B, Pandita RK, Morrow BE: Isolation and characterization of a novel gene containing WD40 repeats from the region deleted in velo-cardio-facial/ DiGeorge syndrome on chromosome 22q11. Genomics 73:264-271, 2001. (Pubitemid 32463722)
18. Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, Inbar D, Steinberg T, Frisch A, Apter A, Weizman A: Me-thylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: An open-label study. J Clin Psychiatry 64:1163-1169, 2003.
19. Goyette CH, Conners CK, Ulrich FR: Normative data on Revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psy-chol 6:221-236, 1978. (Pubitemid 10191762)
20. Green T, Gothelf D, Glaser B, Debbane M, Frisch A, Kotler M, Weizman A, Eliez S: Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome. J Am Acad Child Adolesc Psychiatry 48:1060-1068, 2009.
21. Hagerman RJ, Murphy MA, Wittenberger MD: A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 30:377-392, 1988.
22. Jolin EM, Weller RA, Jessani NR, Zackai EH, McDonald-McGinn DM, Weller EB: Affective disorders and other psychiatric diagnoses in children and adolescents with 22q11.2 Deletion Syndrome. J Affect Disord 119:177-180, 2009.
23. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997. (Pubitemid 27272932)
24. Kerns KA, McInerney R: Preschool Tasks Computer software. BC: University of Victoria, 2007.
25. Kerns KA, Rondeau LA: Development of a continuous performance test for preschool children. J Atten Disord 2:229-238, 1998. (Pubitemid 128703850)
26. Lajiness-O'Neill R, Beaulieu I, Asamoah A, Titus JB, Bawle E, Ahmad S, Kirk JW, Pollack R: The neuropsychological phenotype of velocardiofacial syndrome (VCFS): Relationship to psychopa-thology. Arch Clin Neuropsychol 21:175-184, 2006. (Pubitemid 43117193)
27. National Institutes of Health: Diagnosis, Evaluation, and Treatment of High Blood Pressure, in Children and Adolescents: U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5267, 2005.
28. Nissen SE: ADHD drugs and cardiovascular risk. N Engl J Med 354:1445-1448, 2006.
29. O'Driscoll GA, Depatie L, Holahan AL, Savion-Lemieux T, Barr RG, Jolicoeur C, Douglas VI: Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1452-1460, 2005. (Pubitemid 40798567)
30. Petrides M, Milner B: Deficits on subject-ordered tasks after frontal-and temporal-lobe lesions in man. Neuropsychologia 20:249-262, 1982. (Pubitemid 12090805)
31. Power TJ, Blum NJ, Jones SM, Kaplan PE: Brief report: Response to methylphenidate in two children with Williams syndrome. J Autism Dev Disord 27:79-87, 1997.
32. Rowles BM, Findling RL: Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. Dev Disabil Res Rev 16:273-282, 2010.
33. Samuels JA, Franco K, Wan F, Sorof JM: Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: A double-blind, randomized, cross-over trial. Pediatr Nephrol 21: 92-95, 2006. (Pubitemid 43040200)
34. Schachter HM, Pham B, King J, Langford S, Moher D: How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475-1488, 2001. (Pubitemid 34060190)
35. Shanee N, Apter A, Weizman A: Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population. Isr J Psychiatry Relat Sci 34:179-186, 1997. (Pubitemid 127756848)
36. Shashi V, Keshavan MS, Howard TD, Berry MN, Basehore MJ, Le-wandowski E, Kwapil TR: Cognitive correlates of a functional COMT polymorphism in children with 22q11.2 deletion syndrome. Clin Genet 69:234-238, 2006. (Pubitemid 43354829)
37. Shprintzen RJ: Velo-cardio-facial syndrome: A distinctive behavioral phenotype. Ment Retard Dev Disabil Res Rev 6:142-147, 2000. (Pubitemid 30399538)
38. Silva RR, Skimming JW, Muniz R: Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. Clin Pediatr (Phila) 49:840-851, 2010.
39. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL: Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117:2407-2423, 2008. (Pubitemid 351653546)
40. Wechsler D: Wechsler Intelligence Scale for Children, 3rd edition manual. San Antonio, TX: Psychological Corporation, 1991.
41. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF: Validity of the executive function theory of attention-deficit/hyper-activity disorder: A meta-analytic review. Biol Psychiatry 57:1336-1346, 2005. (Pubitemid 40798553)
42. Woodin M, Wang PP, Aleman D, McDonald-McGinn D, Zackai E, Moss E: Neuropsychological profile of children and adolescents with the 22q11.2 microdeletion. Genet Med 3:34-39, 2001.